Colgate-Palmolive Company vs TransMedics Group Inc — how do they compare? Colgate-Palmolive Company trades at $91.52 (market cap $73.59B), while TransMedics Group Inc trades at $87.99 (market cap $3.10B). The key difference: Colgate-Palmolive Company is far larger — about 23.7× TransMedics Group Inc's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CL | TMDX | |
|---|---|---|
Market Cap | $73.59B | $3.10B |
Sector | Consumer Staples | Technology |
52-Week High | $99.14 | $150.42 |
52-Week Low | $74.98 | $61.99 |
Enterprise Value | $80.07B | $3.49B |
Dividend Yield | 2.3% | — |
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.15, down 0.13% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by emerging markets. However, North American weakness persists, and valuation ratios like P/E of 36.34 and P/B of 311.81 appear elevated. Cash flow remains positive, and a dividend of $0.53 is scheduled for August 2026.
Outlook is mixed: strong brand presence and dividend sustainability support the stock, but high valuation and domestic challenges pose risks. Analyst consensus price target is $99.10, implying modest upside, with 42% buy ratings. Key risks include competitive pressures and margin compression from inflation.
No Aura AI signal available yet.
Trailing returns across standard periods
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →